Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study
Main finding · PROMIS-29 domains (MCID)Result — go to the resultMD 0.2 95% CI 0.1–0.4Authors' conclusion
EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.
Study context
- Population
- Spinal cord stimulation (SCS) candidates with chronic, intractable trunk and/or limb pain, 22 US sites22 US sites
- Exposure
- EVOKE closed-loop SCS: post-implant visit vs trial end
- Outcome
- PROMIS-29 domains and objective neurophysiological metrics, characterised by MCIDs
- Follow-up
- Trial end and maximal analgesic effect post-implant visit
Methodological detailsmulticenter, single-arm, pragmatic, pre-specified subgroup analyses
- Multicenter
- Single-arm
- Pragmatic
- Pre-specified subgroup analyses
Main finding
PROMIS-29 domains (MCID)
MD
0.2
95% CI 0.1–0.4
P = 0.004
Post-implant visit vs Trial end
MD 0.2 (95% CI 0.1–0.4); P = 0.004
As reported in the abstract
- Significantly greater proportion of holistic MCID responders at post-implant visit
- P = 0.047
Observational data: associations, not effects.
Further findings
Delivered therapy (neurophysiological metrics)
- Dose ratio
- 1.3
- Neural dose accuracy
- 2.8 μV
Outcomes by diagnosis (subgroup)
- Similar outcomes across diagnosis subgroups
- Pre-specified
Original publication
Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study. Reg Anesth Pain Med. Published 1 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →